China Biologic Products Inc (CBPO) : Warburg Pincus reduced its stake in China Biologic Products Inc by 99.49% during the most recent quarter end. The investment management company now holds a total of 6,674 shares of China Biologic Products Inc which is valued at $825,173 after selling 1,305,526 shares in China Biologic Products Inc , the firm said in a disclosure report filed with the SEC on Nov 14, 2016.China Biologic Products Inc makes up approximately 0.02% of Warburg Pincus’s portfolio.
Other Hedge Funds, Including , Regents Of The University Of California added CBPO to its portfolio by purchasing 12,600 company shares during the most recent quarter which is valued at $1,557,864. China Biologic Products Inc makes up approx 4.72% of Regents Of The University Of California’s portfolio.Thomas White International Ltd boosted its stake in CBPO in the latest quarter, The investment management firm added 28,295 additional shares and now holds a total of 72,013 shares of China Biologic Products Inc which is valued at $8,717,174. China Biologic Products Inc makes up approx 1.29% of Thomas White International Ltd’s portfolio. Granite Point Capital Management added CBPO to its portfolio by purchasing 13,500 company shares during the most recent quarter which is valued at $1,634,175. China Biologic Products Inc makes up approx 1.45% of Granite Point Capital Management’s portfolio. Daiwa Securities Group sold out all of its stake in CBPO during the most recent quarter. The investment firm sold 500 shares of CBPO which is valued $59,550.
China Biologic Products Inc closed down -0.22 points or -0.19% at $116.32 with 1,18,933 shares getting traded on Monday. Post opening the session at $116, the shares hit an intraday low of $114.91 and an intraday high of $117.06 and the price fluctuated in this range throughout the day.Shares ended Monday session in Red.
On the company’s financial health, China Biologic Products Inc reported $1.01 EPS for the quarter, missing the analyst consensus estimate by $ -0.09 based on the information available during the earnings call on Nov 2, 2016. Analyst had a consensus of $1.10. The company had revenue of $86.53 million for the quarter, compared to analysts expectations of $87.89 million. The company’s revenue was up 9.9% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.82 EPS.
China Biologic Products Inc. (China Biologic) is a biopharmaceutical company. The Company is principally engaged in the research development manufacturing and sales of human plasma-based biopharmaceutical products in China. China Biologic has a product portfolio with over 20 different dosage forms of plasma products. The Company’s principal products are human albumin and immunoglobulin for intravenous injection (IVIG). China Biologic operates its business through two subsidiaries namely Shandong Taibang Biological Products Co. Ltd. and Guizhou Taibang Biological Products Co. Ltd. The Company also holds an interest in Xi’an Huitian Blood Products Co. Ltd. a plasma products company. Its products include human albumin human immunoglobulin IVIG thymopolypeptides injection human hepatitis B immunoglobulin human rabies immunoglobulin human tetanus immunoglobulin placenta polypeptide Factor VIII and human prothrombin complex concentrate (PCC).